What question did this study set out to answer?

This research aims to evaluate the effects of a remote therapeutic monitoring platform on treatment duration and acute care events in patients receiving immune checkpoint inhibitor therapy.

May 29, 2026

Impact of remote therapeutic monitoring on time to discontinuation and acute care events among patients treated with immune checkpoint inhibitors.

Puntos clave

This research aims to evaluate the effects of a remote therapeutic monitoring platform on treatment duration and acute care events in patients receiving immune checkpoint inhibitor therapy.
Analyzed patients with metastatic cancer from four oncology clinics starting ICI treatment from January 2024 to July 2025.
Defined an RTM group based on submission of two ePRO reports within the first 45 days post-treatment.
Assessed time to discontinuation, acute care events, and steroid prescribing using Kaplan-Meier estimation and Cox proportional hazards modeling.
RTM group had a median time to treatment discontinuation of 7.5 months vs. 4.1 months in the control group (p < 0.001).
Hospitalization rates were 6.9% in the RTM group versus 14% in the control group, showing a hazard ratio of 0.51 (p: 0.015).
Steroid use was significantly higher in the RTM group at 53% compared to 31% in the control, with a hazard ratio of 1.69 (p < 0.001).

Resumen

11108 Background: Immune checkpoint inhibitors (ICI) are used to treat several solid tumors but can cause serious toxicities which may lead to early discontinuation of therapy. This study describes the effect of the Canopy electronic patient-reported outcomes (ePROs) -based remote therapeutic monitoring (RTM) platform on time to treatment discontinuation, acute care events, and steroid prescribing in patients receiving ICI therapy. Methods: We studied patients with metastatic cancer from four oncology clinics who started ICI treatment from Jan 1, 2024 to July 20, 2025. An RTM group was defined by submission of two ePRO reports in the first 45 days after first ICI treatment. The control group was never enrolled or did not submit ePRO reports within 45 days. Time to discontinuation (TTD) of ICI, acute care events, and steroid prescribing were assessed using propensity score weighting to account for potential differences in cohort characteristics; costs were taken as rate differences multiplied by average acute care event cost. TTD was assessed by Kaplan-Meier estimation, Cox proportional hazards modeling, and restricted mean survival time at 90 days (RMST). Descriptive statistics were taken about symptoms in the RTM group versus the control group. Results: The study included 363 patients using RTM and 1, 199 in the control group. Lung cancer, melanoma, and kidney cancer were the most frequent diagnoses. In the RTM group time to treatment discontinuation was significantly greater and prescriptions for steroids were more frequent (Table 1). Additionally, RTM use was associated with about a 51% risk of hospitalization (95% CI: 0. 29, 0. 88, p: 0. 015) and 82% risk of ER visits (95% CI: 0. 49, 1. 39, p: 0. 458) compared to the control group. Estimated cost savings in hospitalization associated with RTM use were 11, 733, 933 per 1000 patients treated for one year. Symptoms were detected more frequently in the RTM group compared to the control group, including potentially ICI-related symptoms such as rash (18% vs 3. 2%), diarrhea (28% vs 4. 7%), and difficulty breathing (28% vs 4. 8%). Conclusions: Active ePRO-based RTM with Canopy is associated with increased time to ICI discontinuation and decreased acute care events. Increased use of steroids in patients reporting symptoms suggesting ICI toxicity may explain the beneficial effect of RTM. Weighted analysis outcomes. Outcome RTM group Control group Risk or Hazard RatioRTM / Control (95% CI) Risk or RMST differenceRTM - Control (95% CI) Time to discontinuation Median: 7. 5 mos (95% CI: 6. 7, 8. 8) Median: 4. 1 mos (95% CI: 3. 6, 4. 6) 0. 55 (95% CI: 0. 47 to 0. 64, p < 0. 001) 19 days (16, 22) Hospitalization 6. 9% 14% 0. 51 (0. 29, 0. 88, p: 0. 015) -6. 66 (-11. 02, -2. 13, p: 0. 008) Emergency room visit 9. 9% 12% 0. 82 (0. 49, 1. 39, p: 0. 458) -2. 46 (-8. 05, 2. 95, p: 0. 366) Steroid use 53% 31% 1. 69 (1. 41, 2. 02, p < 0. 001) 21. 67 (13. 90, 29. 13, p < 0. 001)

Me gusta

Guardar